Pharmaceuticals, Biotechnology and Life Sciences
Girish Malhotra, President of EPCOT International, and CPhI Worldwide Annual Industry Report member, discusses the necessity of time reduction for ANDA approvals, arguing that if the current approval time can be reduced from ten months to three months, drug costs will decrease.
Johnson & Johnson <JNJ.N>, Novartis AG <NOVN.S> and Takeda Pharmaceutical Co Ltd <4502.T> have expressed interest in a buyout of the controlling stake that two families have in Brazilian drugmaker Hypermarcas SA <HYPE3.SA>, two people with knowledge of the matter said on Monday
Servier and CTI BioPharma Corp. will expand their agreement regarding Pixuvri, which will give Servier rights to sell it anywhere but…
Orexigen Therapeutics said that Health Canada has accepted to review a New Drug Submission for marketing approval of its products Contrave (naltrexone HCl and bupropion HCl).
Ferring Pharmaceuticals has launched two new resources to help women struggling with infertility. The products were launched during the National Infertility Awarenes Week.
Amgen and Novartis have formed a coalition that will be expanded and, as they hope, bring easier launching of a migraine related product, the USA-based company said late Monday.
Bristol-Myers Squibb and Transgene have entered a new clinical research collaboration to evaluate the safety, tolerability and efficacy of Transgene’s investigational therapeutic vaccine TG4010 in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) + standard chemotherapy (CT) as a first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC) in patients whose tumors have low or undetectable levels of PD-L1.
Novartis’ has posted a first quarter net income down 15% citing a net charge related to the discontinuation of RLX030 ($-0.2 billion), as well as the decline in core operating income.
Bayer has partnered up with Goodbye Malaria to support the objectives of Ending Malaria for Good in Southern Africa.
Eli Lilly’s MONARCH 3 trial has met its primary endpoint of demonstrating statistically significant improvement in progression-free survival (PFS).